Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 503

1.

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.

Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S; Donepezil 401 Study Group..

Neurology. 2004 Aug 24;63(4):651-7.

PMID:
15326237
2.

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.

Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.

Neurology. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03.

PMID:
19176895
3.
4.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
5.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
6.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group..

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
7.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
8.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group..

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
9.

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L.

Int J Geriatr Psychiatry. 2004 Jan;19(1):1-8.

PMID:
14716693
10.
11.

Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.

Doraiswamy PM, Babyak MA, Hennig T, Trivedi R, White WD, Mathew JP, Newman MF, Blumenthal JA.

Psychopharmacol Bull. 2007;40(2):54-62.

PMID:
17514186
12.

Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.

Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, Bahra R; 322 Study Group..

Drugs Aging. 2004;21(1):43-53.

PMID:
14715043
13.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT.

Neurology. 1998 Jan;50(1):136-45.

PMID:
9443470
14.

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.

Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S; Donepezil "402" Study Group..

Arch Neurol. 2004 Dec;61(12):1852-6. Erratum in: Arch Neurol. 2005 May;62(5):825.

PMID:
15596605
15.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

Prasher VP, Huxley A, Haque MS; Down syndrome Ageing Study Group..

Int J Geriatr Psychiatry. 2002 Mar;17(3):270-8.

PMID:
11921156
17.

Donepezil improved memory in multiple sclerosis in a randomized clinical trial.

Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE.

Neurology. 2004 Nov 9;63(9):1579-85.

PMID:
15534239
18.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group..

Neurology. 2001 Aug 28;57(4):613-20. Erratum in: Neurology 2001 Dec 11;57(11):2153.

PMID:
11524468
19.

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.

Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group..

Arch Neurol. 2001 Mar;58(3):427-33.

PMID:
11255446
20.

Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.

Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Takase T, Ohbayashi T.

Dement Geriatr Cogn Disord. 2009;27(3):232-9. doi: 10.1159/000203887.

PMID:
19246907
Items per page

Supplemental Content

Support Center